Digirad IPO Take-Two: Cardiac Gamma Camera Licensing Growth Envisioned
This article was originally published in The Gray Sheet
Executive Summary
Digirad's ability to double revenue while slicing operating costs by almost 64% over the last two years has induced the company to retest the IPO waters